Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
Pohar R, Nkansah E
Record ID 32011001224
English
Authors' recommendations:
In two RCTs, patients with moderate to severe COPD who were treated with tiotropium experienced larger increases in FEV1 than patients treated with ipratropium after four to twelve weeks of treatment. However, other spirometry measures typically did not differ between treatments over this time period. Further, symptoms of COPD did not differ between tiotropium and ipratropium and other important outcomes such as functional capacity and quality of life were not assessed. Thus, it is unclear whether the larger gain in FEV1 that was experienced by patients treated with tiotropium was clinically important or significant from a patient perspective. As such, other factors such as ease of administration, dosing frequency, and cost may be important points to consider when making policy decisions about coverage for these two agents.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Adrenergic beta-Agonists
- Bronchodilator Agents
- Ipratropium
- Pulmonary Disease, Chronic Obstructive
- Scopolamine Derivatives
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.